You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Partner Fund Management | 0 | 1,600,863 | 0 | 3.1% | ||
| Partner Fund Management GP | 0 | 1,600,863 | 0 | 3.1% | ||
| Partner Investment Management | 0 | 20,684 | 0 | Less% | ||
| Partner Investment Management GP | 0 | 20,684 | 0 | Less% | ||
| Brian D. Grossman | 0 | 1,621,547 | 0 | 3.2% | ||
| Christopher M. James | 0 | 1,621,547 | 0 | 3.2% |
Follow Christopher Medlock James's Partner Fund Management
Page 1 of 13 – SEC Filing
| UNITED STATES | |||||||
| SECURITIES AND EXCHANGE COMMISSION | |||||||
| Washington, D.C. 20549 | |||||||
| SCHEDULE 13G | |||||||
| (Rule 13d-102) | |||||||
| Information Statement Pursuant to Rules 13d-1 and 13d-2 | |||||||
| Under the Securities Exchange Act of 1934 | |||||||
| (Amendment No. )* | |||||||
| Coherus BioSciences, Inc. | |||||||
| (Name of Issuer) | |||||||
| Common stock, par value $0.0001 per share | |||||||
| (Title of Class of Securities) | |||||||
| 19249H103 | |||||||
| (CUSIP Number) | |||||||
| June 26, | |||||||
| Date of Event Which Requires Filing of the Statement | |||||||
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
| ¨ | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| ¨ | Rule 13d-1(d) |
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 2 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 2 of 13 Pages |
| 1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Partner Fund Management, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER
1,600,863 shares | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER See Row 6 above | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above | ||
| 10. | CHECK | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.1%1
| ||
| 12. | TYPE OF REPORTING PERSON IA; PN | ||
| 1 | The percentages reported in this Schedule 13G are based upon approximately 51,288,117 shares of common stock outstanding as of April 28, 2017 according Form 10-Q filed by the issuer with the Securities and Exchange Commission on May 8, 2017. All of the other numbers and percentages reported in this Schedule 13G are as of 9:00 a.m. (ET) on the date of filing. |
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 3 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 3 of 13 Pages |
| 1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Partner Fund Management GP, LLC | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER
1,600,863 shares | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER See Row 6 above | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above | ||
| 10. | CHECK | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.1% | ||
| 12. | TYPE OF REPORTING PERSON OO | ||
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 4 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 4 of 13 Pages |
| 1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Partner Investment Management, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER
20,684 shares | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER See Row 6 above | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above | ||
| 10. | CHECK | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) Less than 0.1% | ||
| 12. | TYPE OF REPORTING PERSON IA; PN | ||
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 5 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 5 of 13 Pages |
| 1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Partner Investment Management GP, LLC | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER
20,684 shares | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER See Row 6 above | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above | ||
| 10. | CHECK | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) Less than 0.1% | ||
| 12. | TYPE OF REPORTING PERSON OO | ||
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 6 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 6 of 13 Pages |
| 1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Brian D. Grossman | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER
1,621,547 shares | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER See Row 6 above | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above | ||
| 10. | CHECK | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.2%
| ||
| 12. | TYPE OF REPORTING PERSON IN | ||
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 7 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 7 of 13 Pages |
| 1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Christopher M. James | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER
1,621,547 shares | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER See Row 6 above | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above | ||
| 10. | CHECK | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.2%
| ||
| 12. | TYPE OF REPORTING PERSON IN | ||
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 8 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 8 of 13 Pages |
| Item 1(a) | Name of Issuer |
Coherus BioSciences, Inc.
| Item 1(b) | Address of Issuer’s Principal Executive Offices 333 Twin Dolphin Drive, Suite 600, Redwood City, California 94065 |
| Item 2(a) | Name of Person Filing This Schedule 13G is being jointly filed by Partner Fund Management, L.P. (“PFM”), Partner Fund Management GP, LLC (“PFM-GP”), Partner Investment Management, L.P. (“PIM”), Partner Investment Management GP, LLC (“PIM-GP”), Brian D. Grossman (“Grossman”) and Christopher M. James (“James” and, collectively with PFM, PFM-GP, PIM, PIM-GP and Grossman, the “Reporting Persons”) with respect to shares of common stock (and options to purchase common stock) of the above-named issuer owned by PFM Healthcare Emerging Growth Master Fund, L.P., a Cayman Islands limited partnership (“HEGM”), PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership (“HCM”), PFM Healthcare Opportunities Master Fund, L.P., a Cayman Islands limited partnership (“HCOPP”), PFM Healthcare Long Master Fund, L.P., a Cayman Islands limited partnership (“HCLM”), PFM Oncology Opportunities Master Fund, L.P., a Cayman Islands limited partnership (“ONCOPP”), and PFM Healthcare Principals Fund, L.P., a Delaware limited partnership (“HCP” and, collectively with HEGM, HCM, HCOPP, HCLM and ONCOPP, the “Funds”). |
PFM is the investment advisor for
HEGM, HCM, HCOPP, HCLM and, ONCOPP. PIM is the investment advisor for HCP. PFM-GP and PIM-GP are, respectively, the general partners
of PFM and PIM. Grossman is the portfolio manager for the health care strategy for the Funds. James is the portfolio manager for
the diversified strategy for the Funds. Grossman and James are co-managing members of PFM-GP and PIM-GP.
The filing of this statement shall
not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement
other than the securities actually owned by such person (if any).
| Item 2(b) | Address of Principal Business Office The address of the principal business office of each of the Reporting Persons is c/o Partner Fund Management, L.P., 4 Embarcadero Center, Suite 3500, San Francisco, CA 94111. |
| Item 2(c) | Citizenship Each of PFM and PIM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP and PIM-GP is organized as a limited liability company under the laws of the State of Delaware. Each of Grossman and James is a U.S. citizen. | |
| Item 2(d) | Title of Class of Securities | |
| Common stock, $0.0001 par value | ||
| Item 2(e) | CUSIP Number | |
| 19249H103 |
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 9 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 9 of 13 Pages |
| Item 3 | If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: |
| (a) | [__] | Broker or dealer registered under Section 15 of the Exchange Act; | |
| (b) | [__] | Bank as defined in Section 3(a)(6) of the Exchange Act; | |
| (c) | [__] | Insurance company as defined in Section 3(a)(19) of the Exchange Act; | |
| (d) | [__] | Investment company registered under Section 8 of the Investment Company Act; | |
| (e) | [__] | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); | |
| (f) | [__] | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); | |
| (g) | [__] | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); | |
| (h) | [__] | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; | |
| (i) | [__] | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; | |
| (j) | [__] | Group, in accordance with Rule 13d-1(b)(1)(ii)(J). |
If filing as
a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 10 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 10 of 13 Pages |
| Item 4 | Ownership |
| A. | Partner Fund Management, L.P. and Partner Fund Management GP, LLC |
| (a) | PFM and PFM-GP may be deemed to beneficially own 1,600,863 shares of Common Stock. |
| (b) | The number of shares PFM and PFM-GP may be deemed to beneficially own constitutes approximately 3.1% of the Common Stock outstanding. |
| (c) | Number of shares as to which such person has: |
| (i) | sole power to vote or to direct the vote: 0 |
| (ii) | shared power to vote or to direct the vote: 1,600,863 |
| (iii) | sole power to dispose or to direct the disposition of: 0 |
| (iv) | shared power to dispose or to direct the disposition of: 1,600,863 |
| B. | Partner Investment Management, L.P. and Partner Investment Management GP, LLC |
| (a) | PIM and PIM-GP may be deemed to beneficially own 20,684 shares of Common Stock. |
| (b) | The number of shares PIM and PIM-GP may be deemed to beneficially own constitutes less than 0.1% of the Common Stock outstanding. |
| (c) | Number of shares as to which such person has: |
| (i) | sole power to vote or to direct the vote: 0 |
| (ii) | shared power to vote or to direct the vote: 20,684 |
| (iii) | sole power to dispose or to direct the disposition of: 0 |
| (iv) | shared power to dispose or to direct the disposition of: 20,684 |
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 11 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 11 of 13 Pages |
| C. | Brian D. Grossman |
| (a) | Grossman may be deemed to beneficially own 1,621,547 shares of Common Stock. |
| (b) | The number of shares Grossman may be deemed to beneficially own constitutes approximately 3.2% of the Common Stock outstanding. |
| (c) | Number of shares as to which such person has: |
| (i) | sole power to vote or to direct the vote: 0 |
| (ii) | shared power to vote or to direct the vote: 1,621,547 |
| (iii) | sole power to dispose or to direct the disposition of: 0 |
| (iv) | shared power to dispose or to direct the disposition of: 1,621,547 |
| D. | Christopher M. James |
| (a) | James may be deemed to beneficially own 1,621,547 shares of Common Stock. |
| (b) | The number of shares James may be deemed to beneficially own constitutes approximately 3.2% of the Common Stock outstanding. |
| (c) | Number of shares as to which such person has: |
| (i) | sole power to vote or to direct the vote: 0 |
| (ii) | shared power to vote or to direct the vote: 1,621,547 |
| (iii) | sole power to dispose or to direct the disposition of: 0 |
| (iv) | shared power to dispose or to direct the disposition of: 1,621,547 |
| Item 5 | Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x. |
| Item 6 | Ownership of More than Five Percent on Behalf of Another Person |
Not Applicable
| Item 7 | Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company |
See Item 2 above
| Item 8 | Identification and Classification of Members of the Group |
Not Applicable
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 12 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 12 of 13 Pages |
| Item 9 | Notice of Dissolution of Group |
Not Applicable
| Item 10 | Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. |
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Follow Coherus Biosciences Inc. (NASDAQ:CHRS)
Page 13 of 13 – SEC Filing
| CUSIP No. 19249H103 | 13G | Page 13 of 13 Pages |
After reasonable inquiry
and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true,
complete and correct.
Dated this 6th day of July, 2017.
| PARTNER FUND MANAGEMENT, L.P. | PARTNER FUND MANAGEMENT GP, LLC | |||
| By: | Partner Fund Management GP, LLC | By: | /s/ Darin Sadow | |
| its general partner | Darin Sadow, Authorized Signatory | |||
| By: | /s/ Darin Sadow | |||
| Darin Sadow, Authorized Signatory | ||||
| PARTNER INVESTMENT MANAGEMENT, L.P. | PARTNER INVESTMENT MANAGEMENT GP, LLC | |||
| By: | Partner Investment Management GP, LLC, | By: | /s/ Darin Sadow | |
| its general partner | Darin Sadow, Authorized Signatory | |||
| By: | /s/ Darin Sadow | |||
| Darin Sadow, Authorized Signatory | ||||
| BRIAN D. GROSSMAN | CHRISTOPHER M. JAMES | |||
| By: | /s/ Darin Sadow | By: | /s/ Darin Sadow | |
| Darin Sadow, attorney-in-fact* | Darin Sadow, attorney-in-fact** | |||
| * | Darin Sadow is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011. |
| ** | Darin Sadow is signing on behalf of Christopher M. James as attorney-in-fact pursuant to a power of attorney dated August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011. |
